PCOS Renamed to PMOS to Improve Diagnosis and Treatment

Photo Courtesy: https://research.monash.edu/

Researchers led by Professor Helena Teede announced in Prague on May 12, 2026, that Polycystic Ovary Syndrome (PCOS) will now be called polyendocrine metabolic ovarian syndrome (PMOS) to better reflect the condition’s hormonal and metabolic effects and improve diagnosis and care for millions of women worldwide.

The name change was published in The Lancet, a medical journal, following a 14-year global collaboration involving researchers, doctors, patient groups, and more than 50 medical organizations. Experts explained that the old name “PCOS” was often misleading because not all patients develop ovarian cysts, causing confusion, delayed diagnosis, and inadequate treatment.

PMOS affects around 170 million women worldwide and is considered one of the leading causes of infertility. The disorder is linked to hormonal imbalance, irregular menstruation, acne, weight gain, insulin resistance, diabetes, and mental health concerns.

According to researchers, the new name emphasizes that the condition is not only ovarian but also a complex metabolic and endocrine disorder that affects multiple body systems. Health experts hope the updated term will help improve awareness, reduce stigma, and encourage earlier medical intervention.

Medical organizations are expected to gradually adopt the new term PMOS in healthcare guidelines, research studies, and public awareness campaigns over the next few years.